Biogen Idec Ma Inc.

Biogen, Incorporated

The Faculty of Medicine of the University of Geneva

University of California

New York University

Biogen Ma Inc.

Other

The University of North Carolina at Chapel Hill

Emory University

Apoxis S.a.

Topotarget Switzerland Sa

Biogen Idcc Ma Inc.

Apotech R&d S.a.

Jeffrey L Browning

Paula S Hochman

Christopher D Benjamin

Werner Meier

Fabienne MacKay

Pascal Schneider

Christine Ambrose

Jurg Tschopp

Paul David Rennert

Jeffrey Thompson

Carl F Ware

Vincent K Tsiagbe

Konrad Miatkowski

Jeanette Thorbecke

Yves Chicheportiche

R Blake Pepinsky

Ellen A Garber

Barbara P Wallner

Linda C Burkly

Veronique Bailly

Timothy Zheng

Aniela Jakubowski

Fabienne Mackay

Yves Chichportiche

Sha Mi

Rafi Ahmed

Jenny P-y Ting

Graham K Farrington

Evan Beckman

Maryann Puglielli

A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

Methods of modulating immune responses using BCMA polypeptide

Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA)

Methods of screening for a compound that inhibits the interaction between BAFF and BCMA

Methods for high level expression of active lymphotoxin-&#x3b2; receptor immunoglobulin chimeric proteins and their purification.

Method for increasing expression of active tumor necrosis factor receptor family member-Ig fusion proteins

This invention relates to compositions and methods comprising 'lymphotoxin-&#x3b2;-receptor blocking agents', which block lymphotoxin-&#x3b2; receptor signalling. Lymphotoxin-&#x3b2; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&#x3b2; receptor extracellular domain that act as lymphotoxin-&#x3b2; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&#x3b2; receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&#x3b2; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&#x3b2; receptor signalling is provided.

Methods for inhibiting lymphotoxin-&#x3b2; receptor signaling in TH1 cell-associated disorders

This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.

Compositions comprising variant LT-B-R-IG fusion proteins

Compositions and methods comprising 'lymphotoxin-&#x3b2; receptor blocking agents' which block lymphotoxin-&#x3b2; receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.

Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases

Method for the high level expression of active tumor necrosis receptor family member immunoglobulin fusion proteins

Therapeutic uses of inhibitors of the lymphotoxin pathway to treat tumors, specifically to treat follicular lymphomas.

Treatment of follicular lymphomas using inhibitors of the LT pathway

Methods of treating a demyelinating disorder using inhibitors of the lymphotoxin pathway.

Treatment of demyelinating disorders with soluble lymphotoxin-&#x3b2;-receptor

This invention relates to compositions and methods comprising 'lymphotoxin-&#x3b2;-receptor blocking agents', which block lymphotoxin-&#x3b2; receptor signalling. Lymphotoxin-&#x3b2; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&#x3b2;.receptor extracellular domain that act as lymphotoxin-&#x3b2; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&#x3b2;. receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&#x3b2; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&#x3b2; receptor signalling is provided.

Soluble lymphotoxin-&#x3b2; receptor fusion protein and methods for inhibiting lymphotoxin &#x3b2;-receptor signaling

Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.

Methods of decreasing tumor volume and reducing tumor burden using TNF-receptor-coupling agents

The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.

Methods of promoting neurite outgrowth with soluble TAJ polypeptides

Receptor coupling agents and compositions thereof

Compositions and methods comprising 'lymphotoxin-&#x3b2; receptor blocking agents' which block lymphotoxin-&#x3b2; receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.

Growing community of inventors

Cambridge, MA, United States of America

Jeffrey L Browning